We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) recently announced favorable data from the “Effectiveness of medium cut-off versus high flux dialyzers: An inverse probability weighting cohort study”. The data demonstrates that expanded hemodialysis (HDx) therapy, enabled by the Theranova dialyzer, is likely to reduce cardiovascular events by 35% and hospitalization rates by 18%.
The data announced was according to a new, large, multicenter, retrospective study conducted on Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.
For investors’ note, Theranova is currently used in various countries, including the United States. Notably, it was granted a De Novo application by the FDA, which established a new classification of dialyzer technology with unique performance standards. Interestingly, such designations are rarely granted in the dialysis space.
With the latest positive study results, Baxter’s Renal Care business is expected to gain a solid foothold in the global arena.
Significance of the Data
Theranova was developed to provide HDx therapy so as to filter a wider array of molecules from the blood unlike traditional hemodialysis filters. This effective removal of conventional and large middle molecules allows for filtration almost similar to that of the kidney. Notably, these large middle molecules are feared to be associated with inflammation and cardiovascular disease in patients with kidney failure.
Per management, the new findings associated with Theranova-enabled HDx therapy largely support the evidence that patients with kidney disease who are on the therapy may see improved clinical outcomes and lower healthcare resource utilization.
Industry Prospects
Per a report by Research and Markets, the global hemodialysis market was valued at $78.30 billion in 2019 and is estimated to reach $116.66 billion by 2030 at a CAGR of 3.6%. Factors like rising incidences of renal issues, growing occurrence of diabetes and hypertension, and shortage of kidney donors are likely to drive the market.
Given the market potential, the latest favorable data is expected to provide a significant boost to Baxter’s business globally.
Recent Developments in Renal Care
Of late, Baxter has witnessed a few notable developments across its renal care business.
The company, this month, announced the launch of the Sharesource Analytics 1.0 premium module, the next generation of digital health for home-based peritoneal dialysis (“PD”) patients.
In May, Baxter announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of continuous renal replacement therapy and other organ-support therapies while allowing hospitals the flexibility to meet ICU requirements.
The company, in April, reported solid worldwide sales during first-quarter 2021. Robust renal care revenues resulted from global growth in Baxter’s PD business.
Price Performance
Shares of the company have lost 6.6% in the past year against the industry’s 10.1% growth and the S&P 500's 34.6% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Amedisys, Inc. (AMED - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Image: Bigstock
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
Baxter International Inc. (BAX - Free Report) recently announced favorable data from the “Effectiveness of medium cut-off versus high flux dialyzers: An inverse probability weighting cohort study”. The data demonstrates that expanded hemodialysis (HDx) therapy, enabled by the Theranova dialyzer, is likely to reduce cardiovascular events by 35% and hospitalization rates by 18%.
The data announced was according to a new, large, multicenter, retrospective study conducted on Colombian dialysis patients treated with long-term HDx compared to propensity-matched patients treated with High-Flux Hemodialysis.
For investors’ note, Theranova is currently used in various countries, including the United States. Notably, it was granted a De Novo application by the FDA, which established a new classification of dialyzer technology with unique performance standards. Interestingly, such designations are rarely granted in the dialysis space.
With the latest positive study results, Baxter’s Renal Care business is expected to gain a solid foothold in the global arena.
Significance of the Data
Theranova was developed to provide HDx therapy so as to filter a wider array of molecules from the blood unlike traditional hemodialysis filters. This effective removal of conventional and large middle molecules allows for filtration almost similar to that of the kidney. Notably, these large middle molecules are feared to be associated with inflammation and cardiovascular disease in patients with kidney failure.
Per management, the new findings associated with Theranova-enabled HDx therapy largely support the evidence that patients with kidney disease who are on the therapy may see improved clinical outcomes and lower healthcare resource utilization.
Industry Prospects
Per a report by Research and Markets, the global hemodialysis market was valued at $78.30 billion in 2019 and is estimated to reach $116.66 billion by 2030 at a CAGR of 3.6%. Factors like rising incidences of renal issues, growing occurrence of diabetes and hypertension, and shortage of kidney donors are likely to drive the market.
Given the market potential, the latest favorable data is expected to provide a significant boost to Baxter’s business globally.
Recent Developments in Renal Care
Of late, Baxter has witnessed a few notable developments across its renal care business.
The company, this month, announced the launch of the Sharesource Analytics 1.0 premium module, the next generation of digital health for home-based peritoneal dialysis (“PD”) patients.
In May, Baxter announced the global launch of the latest version of its next-generation platform, PrisMax 2. The PrisMax 2 system aims to help streamline the delivery of continuous renal replacement therapy and other organ-support therapies while allowing hospitals the flexibility to meet ICU requirements.
The company, in April, reported solid worldwide sales during first-quarter 2021. Robust renal care revenues resulted from global growth in Baxter’s PD business.
Price Performance
Shares of the company have lost 6.6% in the past year against the industry’s 10.1% growth and the S&P 500's 34.6% rise.
Zacks Rank & Key Picks
Currently, Baxter carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Amedisys, Inc. (AMED - Free Report) , AMN Healthcare Services Inc (AMN - Free Report) and National Vision Holdings, Inc. (EYE - Free Report) .
Amedisys’ long-term earnings growth rate is estimated at 12%. The company presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare’s long-term earnings growth rate is estimated at 6.5%. It currently carries a Zacks Rank #2.
National Vision’s long-term earnings growth rate is estimated at 23%. It currently sports a Zacks Rank #1.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure>>